Scaling Biotech Without Breaking the Science
Event Description
Biotech companies face a unique challenge: investors expect startup speed, while science demands precision.
From the moment a company raises its first institutional round, founders are balancing competing priorities—building a team, managing burn, accelerating R&D, raising the next round, navigating regulatory milestones, and maintaining scientific integrity under increasing pressure.
This session brings together founders, investors, operators, and people leaders to discuss what it actually takes to scale a biotechnology company responsibly. Rather than focusing solely on fundraising, the conversation explores the operational decisions that determine whether companies can sustain growth while continuing to deliver rigorous science, attract exceptional talent, and build organizations that last.
You’ll Learn
The founder's balancing act: Meeting investor expectations while protecting the integrity of the science
Building teams that can scale: Hiring, culture, leadership, and organizational design
Capital as a strategic tool: How fundraising decisions shape hiring, milestones, and long-term growth
Managing burn while investing in science: Prioritizing resources without sacrificing innovation
Preparing for the next stage: Operational readiness from Seed through Series A and beyond
Avoiding common scaling mistakes: Lessons from founders, investors, and operators who have been through it
Who Should Attend?
• Biotech founders
• Scientists interested in commercialization
• Graduate students & postdocs
• Investors
• Operators and startup advisors